6Blommel ML, Blommel AL. Dabigatran etexilate: a novel o-ral direct thrombin inhibitor [J]. Am J Health Syst Pham, 2011,68(16) : 1506.
7Fuster V, Ryden LE, Cannom DS, et al . ACC, AHA/ESC 2006 Guide-lines for the management of patients with atrial fibrillation~ a report of the American College of Cardiology/ American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for prac- tice guidelines (writing committee to revise the 2001 guide- lines for the management of patients with atrial fibrillation) : developed in collaboration with the European Heart Rhythm Association and the heart rhythm society E J]. Circulation, 2006,114(7) : e257-e354.
8Lip GY, Nieuwlaat R, Pisters R, et al . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest, 2010, 137 (2) :263-272.
9Paikin JS, Haroun MJ, Eikeiboom JW. Dabigatran for stroke prevention in atrial fibrillation: The RE-LY trial [J]. Expert Rev Cardiovasc Ther , 2011,9(3):279-286.
